were no statistically significant differences in the change from baseline in treatment comfort between combination and each of the monotherapy groups treatment satisfaction was better than baseline for a statistically significantly greater percentage of patients in the combination group 23 4 36 154 than in the brimonidine group 13 2 20 151 p 0 005 a total of 19 9 30 151 of patients in the timolol group reported better treatment satisfaction than baseline through month 3 of the study 53 4 103 193 of patients in the combination group 61 7 121 196 of the brimonidine group and 50 8 100 197 of the timolol group experienced one or more adverse events regardless of causality the incidences of oral dryness eye pruritus foreign body sensation and conjunctival folliculosis were statistically significantly lower with the combination than with brimonidine p u2266 0 034 while burning and stinging were statistically significantly higher with the combination than with brimonidine p u2266 0 028 there were no statistically significant differences in adverse events between the combination and timolol except for a statistically significantly higher incidence of eye discharge with the combination 2 6 5 193 compared to timolol 0 0 197 p 0 029 the most frequently reported adverse events gt 3 in any treatment group were as follows tabulated by descending order in the combination group combination brimonidine timolol preferred term n 193 n 196 n 197 burning sensation in eye 23 11 9 11.